ReportWire

Tag: Pharmaceutical manufacturing

  • Pharma manufacturer getting IDA help for expansion | Long Island Business News

    [ad_1]

    and its affiliate, AiPing Pharmaceuticals, received preliminary approval for economic incentives from the Suffolk County Industrial Development Agency for a planned . 

    The $6.7 million project includes the conversion of existing warehouse space to a production and manufacturing area to accommodate additional employees and machinery required for the company to transition to prescription pharmaceutical operations, according to an IDA statement. 

    The project is expected to add 35 jobs to the company’s existing staff of 162. 

    A&Z currently uses its buildings for domestic sales and as a laboratory, research and development, and manufacturing site for the export of over-the-counter pharmaceuticals, nutraceuticals and prescription pharmaceuticals for sale in the domestic market. 

    In addition to its over-the-counter medications and nutraceuticals, A&Z’s facility is also FDA-registered to manufacture such prescription drugs as Amitriptyline HCl, which is used to treat depression; Buspirone, which is used to treat generalized anxiety disorder; Meloxicam, which is used for arthritis pain management; and Metformin HCl, which is used to treat diabetes, according to the IDA. The company added 20 FDA prescription drug licenses this year and could add another 10 licenses in 2026. 

    “We are grateful for the continued partnership of the Suffolk County Industrial Development Agency,” CEO Emma Li Xu, A&Z’s founder, said in the statement. “With the IDA’s critical support, we can move more of our manufacturing and development to Suffolk County.” 

    Xu started A&Z with four people 30 years ago after working in China, Hong Kong, and Australia, according to the IDA. 

    “A& Z Pharmaceutical has been a leading manufacturer for 30 years in the global pharmaceutical and growing supplement market,” Kelly Murphy, executive director of the Suffolk IDA, said in the statement. “This project will strengthen A&Z’s manufacturing capabilities and support the continued growth of Suffolk County’s manufacturing and pharmaceutical industry. Projects like this ensure that Suffolk continues to be a hub for innovation, high-quality jobs, and long-term economic vitality.” 


    [ad_2]

    David Winzelberg

    Source link

  • Gemini Pharma getting IDA aid for $13.9M Suffolk expansion | Long Island Business News

    [ad_1]

    has been granted preliminary approval from the Industrial Development Agency for financial incentives that will assist with $13.9 million in renovations to four properties. 

    The 43-year-old family-owned manufacturer of over-the-counter pharmaceutical, nutraceutical and animal products is planning infrastructure improvements and other upgrades that aim to expand its operations. 

    The projects include repurposing underutilized office space to create about 4,000 square feet of R&D and support space at 65 Mall Drive in Commack; replacing an aging 5,500-gallon wastewater tank with a direct municipal sewer connection at 55 Adams Ave. in Hauppauge; enhancements to the company’s manufacturing facility at 81 Modular Drive in Commack; and renovations of its corporate headquarters at 87 Modular Ave. in Commack, according to Gemini’s IDA application. 

    “This project not only strengthens Gemini Pharmaceuticals’ future but also fuels the continued growth of Suffolk County’s already robust pharmaceutical industry,” Kelly Murphy, executive director of the Suffolk IDA, said in an agency statement. “By supporting strategic investments like this, we’re ensuring that Suffolk remains a hub for innovation, high-quality jobs, and long-term economic vitality.” 

    The project is expected to retain 256 jobs and create an additional 50 jobs over the next two years. It is projected to be completed in 2027. 

    “We are truly grateful for the support of the Suffolk County IDA,” Michael Finamore, CEO of Gemini Pharmaceuticals, said in the statement. “This project would not be possible without their partnership. With this investment, we can upgrade our facilities, expand our capabilities, and continue to provide stable, high-quality jobs here in Suffolk County.” 


    [ad_2]

    David Winzelberg

    Source link

  • Twitter Blue signups unavailable after raft of fake accounts

    Twitter Blue signups unavailable after raft of fake accounts

    [ad_1]

    Twitter’s relaunched premium service — which grants blue-check “verification” labels to anyone willing to pay $8 a month — was unavailable Friday after the social media platform was flooded by a wave of imposter accounts it itself had approved.

    It’s the latest whiplash-inducing change to the service where uncertainty has become the norm since billionaire Elon Musk took control two weeks ago. Prior to that, the blue check was granted to government entities, corporations, celebrities and journalists verified by the platform — precisely to prevent impersonation. Now, anyone can get one as long as they have a phone, a credit card and $8 a month.

    An impostor account posing as pharmaceutical giant Eli Lilly & Co. and registered under the revamped Twitter Blue system tweeted that insulin was free, forcing the Indianapolis company to post an apology. Nintendo, Lockheed Martin, Musk’s own companies Tesla and SpaceX were also impersonated, as well as the accounts of various professional sports and political figures.

    For advertisers who have put their business with Twitter on hold, the fake accounts could be the last straw: Musk’s rocky run atop the platform — laying off half its workforce and triggering high-profile departures — has raised questions about its survivability.

    The impostors can cause big problems, even if they’re taken down quickly.

    They have created “overwhelming reputational risk for placing advertising investments on the platform,” said Lou Paskalis, longtime marketing and media executive and former Bank of America head of global media. Adding that with the fake “verified” brand accounts, “a picture emerges of a platform in disarray that no media professional would risk their career by continuing to make advertising investments on, and no governance apparatus or senior executive would condone if they did.”

    Adding to the confusion, Twitter now has two categories of “blue checks,” and they look identical. One includes the accounts verified before Musk took helm. It notes that “This account is verified because it’s notable in government, news, entertainment, or another designated category.” The other notes that the account subscribes to Twitter Blue.

    But as of midday Friday, Twitter Blue was not available for subscription.

    On Thursday, Musk tweeted that “too many corrupt legacy Blue ‘verification’ checkmarks exist, so no choice but to remove legacy Blue in coming months.”

    An email sent to Twitter’s press address went unanswered. The company’s communications department was gutted in the layoffs and Twitter has not responded to queries from The Associated Press since Oct. 27 when Musk took the helm.

    Thursday night, Twitter also once again began adding gray “official” labels to some prominent accounts. It had rolled out the labels earlier this week, only to kill them a few hours later.

    They returned Thursday night, at least for some accounts — including Twitter’s own, as well as big companies like Amazon, Nike and Coca-Cola, before many vanished again.

    Celebrities also did not appear to be getting the “official” label.

    Twitter is heavily dependent on ads and about 90% of its revenue comes from advertisers. But each change that Musk is rolling out — or rolling back — makes the site less appealing for big brands.

    “It has become chaos,” said Richard Levick, CEO of public relations firm Levick. “Who buys into chaos?”

    A bigger issue for Musk might be the risk to his reputation as a model tech executive, since the rollout of different types of verifications and other changes have been botched, Levick added.

    “It’s another example something not very well thought out, and that’s what happens when you rush,” Levick said. “Musk has been known as a trusted visionary and magician — he can’t lose that moniker and that’s what’s at risk right now,” Levick said.

    Twitter is a small part of total ad spending for the biggest companies that advertise on the platform. Google, Amazon and Meta account for about 75% of digital ads globally, with all other platforms combined making up the other 25%. Twitter accounts for about 0.9% of global digital ad spending, according to Insider Intelligence.

    “For most marketers on budgets, Twitter has always been that thing that is potentially too big to totally ignore but not quite big enough to care about,” said Mark DiMassimo, creative chief of marketing agency DiGo.

    “None of this is a forever moral or ethical stand on the point of advertisers,” he added. “If Musk proves to be a civilizing force in the long run advertisers will come back — if Twitter is still there. It’s a ‘for now’ decision — why be there now?”

    ———

    AP Technology Writer Frank Bajak in Boston contributed to this report.

    [ad_2]

    Source link

  • Twitter Blue signups unavailable after raft of fake accounts

    Twitter Blue signups unavailable after raft of fake accounts

    [ad_1]

    Twitter’s relaunched premium service — which grants blue-check “verification” labels to anyone willing to pay $8 a month — was unavailable Friday after the social media platform was flooded by a wave of imposter accounts approved by Twitter.

    Before billionaire Elon Musk took control of the social media platform two weeks ago the blue check was granted to celebrities, journalists and verified by the platform — precisely to prevent impersonation. Now, anyone can get one as long as they have a phone, a credit card and $8 a month.

    After an imposter account registered under the revamped Twitter Blue system tweeted that insulin was free, pharmaceutical giant Eli Lilly & Co. had to post an apology. Nintendo, Lockheed Martin, Musk’s own Tesla and SpaceX were also impersonated as well as the accounts of various professional sports figures.

    For advertisers who have put their business in Twitter on hold, the fake accounts could be the last straw as Musk’s rocky run atop the platform — laying off half the workforce and triggering high-profile departures — raises questions about its survivability.

    There are now two categories of “blue checks,” and they look identical. One includes the accounts verified before Musk took helm. It notes that “This account is verified because it’s notable in government, news, entertainment, or another designated category.” The other notes that the account subscribes to Twitter Blue.

    An email sent to Twitter’s press address went unanswered. The company’s communications department was gutted in the layoffs.

    On Thursday, Musk tweeted that “too many corrupt legacy Blue ‘verification’ checkmarks exist, so no choice but to remove legacy Blue in coming months.”

    Twitter Blue was not available on the platform’s online version, which said signup was only possible on the iPhone version. But the iPhone version did not offer Twitter Blue as an option

    Twitter also once again began adding gray “official” labels to some prominent accounts. It had rolled out the labels earlier this week, only to kill them a few hours later.

    They returned Thursday night, at least for some accounts — including Twitter’s own, as well as big companies like Amazon, Nike and Coca-Cola, before many vanished again.

    Celebrities also did not appear to be getting the “official” label.

    AP Technology Writer Frank Bajak in Boston contributed to this report.

    [ad_2]

    Source link

  • Pfizer says COVID-19 vaccine will cost $110-$130 per dose

    Pfizer says COVID-19 vaccine will cost $110-$130 per dose

    [ad_1]

    Pfizer will charge $110 to $130 for a dose of its COVID-19 vaccine once the U.S. government stops buying the shots, but the drugmaker says it expects many people will continue receiving it for free.

    Pfizer executives said the commercial pricing for adult doses could start early next year, depending on when the government phases out its program of buying and distributing the shots.

    The drugmaker said it expects that people with private health insurance or coverage through public programs like Medicare or Medicaid will pay nothing. The Affordable Care Act requires insurers to cover many recommended vaccines without charging any out-of-pocket expenses.

    A spokesman said the company also has an income-based assistance program that helps eligible U.S. residents with no insurance get the shots.

    The price would make the two-dose vaccine more expensive for cash-paying customers than annual flu shots. Those can range in price from around $50 to $95, depending on the type, according to CVS Health, which runs one of the nation’s biggest drugstore chains.

    A Pfizer executive said Thursday that the price reflects increased costs for switching to single-dose vials and commercial distribution. The executive, Angela Lukin, said the price was well below the thresholds “for what would be considered a highly effective vaccine.”

    The drugmaker said last year that it was charging the U.S. $19.50 per dose, and that it had three tiers of pricing globally, depending on each country’s financial situation. In June, the company said the U.S. government would buy an additional 105 million doses in a deal that amounted to roughly $30 per shot. The government has the option to purchase more doses after that.

    Pfizer’s two-shot vaccine debuted in late 2020 and has been the most common preventive shot used to fight COVID-19 in the U.S.

    More than 375 million doses of the original vaccine, which Pfizer developed with the German drugmaker BioNTech, have been distributed in the U.S., according to the Centers for Disease Control and Prevention.

    That doesn’t count another 12 million doses of an updated booster that was approved earlier this year.

    The vaccine brought in $36.78 billion in revenue last year for Pfizer and was the drugmaker’s top-selling product.

    Analysts predict that it will rack up another $32 billion this year, according to FactSet. But they also expect sales to fall rapidly after that.

    More than 90% of the adult U.S. population has already received at least one dose of COVID-19 vaccine, according to the CDC. But only about half that population has also received a booster dose.

    ———

    The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.

    [ad_2]

    Source link